Technical Articles

This article systematically elucidates the pathological role of CDK6 in myelofibrosis and its potential as a therapeutic target. It highlights the upregulated expression of CDK6 in MPN/MF hematopoietic progenitor cells and its molecular mechanisms in driving myelofibrosis through the regulation of Aurora kinase, NF-κB, and TGF-β signaling pathways. The study also analyzes the efficacy validation of CDK4/6 inhibition strategies in MF models and explores the novel approach of CDK6-targeted degradation using CRBN-based PROTAC technology.